Mp71-08 trends over 20 years of antimicrobial prophylaxis for artificial urinary sphincter surgery

You have accessJournal of UrologyCME1 Apr 2023MP71-08 TRENDS OVER 20 YEARS OF ANTIMICROBIAL PROPHYLAXIS FOR ARTIFICIAL URINARY SPHINCTER SURGERY Helen Sun, Michael Callegari, Eric Zhou, Stephen Rhodes, Aaron Brant, Erin Jesse, Megan Prunty, Jonathan Shoag, Kyle Scarberry, and Shubham Gupta Helen SunHelen Sun More articles by this author , Michael CallegariMichael Callegari More articles by this author , Eric ZhouEric Zhou More articles by this author , Stephen RhodesStephen Rhodes More articles by this author , Aaron BrantAaron Brant More articles by this author , Erin JesseErin Jesse More articles by this author , Megan PruntyMegan Prunty More articles by this author , Jonathan ShoagJonathan Shoag More articles by this author , Kyle ScarberryKyle Scarberry More articles by this author , and Shubham GuptaShubham Gupta More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003339.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Perioperative antimicrobial prophylaxis is crucial for prevention of patient morbidity after artificial urinary sphincter (AUS) placement. While antibiotic guidelines exist for urologic procedures, adoption patterns for AUS surgery are unclear. We aimed to assess trends in antibiotic prophylaxis for AUS and outcomes relative to American Urological Association (AUA) best practice statements. METHODS: The Premier Healthcare Database was queried from 2000 to 2020. Encounters involving AUS insertion, removal, and/or associated complications were identified via ICD and CPT codes. Premier charge codes were used to identify antibiotics used during the insertion encounter. Guideline-based regimens were defined as 1) aminoglycoside (AG) + 1st/2nd generation cephalosporin (CEP), 2) AG+vancomycin, 3) aztreonam and CEP, 4) aztreonam and vancomycin, 5) aminopenicillin, or 6) beta-lactamase inhibitor. AUS-related complication events were found using patient hospital identifiers. Univariable analysis between hospital/patient characteristics and use of guideline-based antibiotics was done via chi-squared and Kruskal Wallis tests. A logistic regression model was used to determine the odds ratio (OR) of complications. RESULTS: Of 9794 patients with primary AUS surgery, 4318 (44%) received guideline-based antibiotics. Probability of guideline-based regimen use increased 7.5% per year. Patients with guideline-based regimens had lower odds of any complication within 3 months vs. non-guideline regimens (OR 0.76, 95% CI 0.67-0.86); however, no significant difference in repair/removal was noted (OR 0.99, 95% CI 0.86-1.14). Each decade increase in age was associated with a 17% increase in complications (95% CI 1.11-1.24). No significant difference was noted with Charlson comorbidity index, region, or hospital size. CONCLUSIONS: Adherence to AUA antimicrobial guidelines for AUS surgery appears to have increased over time. Use of guideline-based regimens was associated with lower likelihood of complications, however they did not appear to lower surgical revision rates. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1016 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Helen Sun More articles by this author Michael Callegari More articles by this author Eric Zhou More articles by this author Stephen Rhodes More articles by this author Aaron Brant More articles by this author Erin Jesse More articles by this author Megan Prunty More articles by this author Jonathan Shoag More articles by this author Kyle Scarberry More articles by this author Shubham Gupta More articles by this author Expand All Advertisement PDF downloadLoading ...